An official website of the United States government
Evaluation of EBUS-TBNA versus EBUS-TBNA plus Transbronchial Mediastinal Cryobiopsy to Obtain Adequate Tissue Samples for Next Generation Sequencing, META-Gen Trial
Trial Status: active
This phase III trial compares how well endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) versus EBUS-TBNA plus transbronchial mediastinal cryobiopsy works to obtain adequate tissue samples for next generation sequencing (NGS). During usual care, if there is suspicion of cancer, a procedures known as an EBUS-TBNA is done to take sample of lymph nodes to evaluate for cancer spread. If there is suspected cancer in the lymph nodes, multiple samples are taken for molecular testing (NGS) to help guide treatment decisions. It requires a certain amount of tissue to send for the molecular testing which can be achieved with EBUS-TBNA about 70% of the time. Researchers want to find out if adding a biopsy tool currently used in usual care, known as a cryoprobe, can acquire more tissue for molecular analysis. The cryoprobe uses a freezing technique to biopsy and can potentially gather larger and higher quality tissue samples than the standard EBUS-TBNA method.
Inclusion Criteria
Mediastinal lesion (lymph node or mass) on endobronchial ultrasound (EBUS) and/or positron emission tomography/computed tomography (PET/CT) concerning for primary or metastatic malignancy
Malignant cells present on rapid on-site cytological evaluation (ROSE)
Exclusion Criteria
Patient is known to be less than 18 years old
Patient is known to be pregnant
Patient is known to be a prisoner
Operator deems lesion is not safe to biopsy
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06105801.
Locations matching your search criteria
United States
Maryland
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer Center
I. To evaluate the utility of adding transbronchial mediastinal cryobiopsy to endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) on its ability to improve the likelihood of acquiring tissue sufficient for next-generation sequencing (NGS).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo bronchoscopy and EBUS-TBNA on study.
ARM II: Patients undergo bronchoscopy and EBUS-TBNA with transbronchial mediastinal cryobiopsy on study.
Upon completion of study intervention, patients are followed up to 30 days.
Trial PhasePhase III
Trial Typediagnostic
Lead OrganizationVanderbilt University/Ingram Cancer Center